Compare Johnson & Johnson (JNJ) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs DENTSPLY SIRONA Inc — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while DENTSPLY SIRONA Inc trades at $8.83 (market cap $1.73B). The key difference: Johnson & Johnson is far larger — about 357.3× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| JNJ | XRAY | |
|---|---|---|
Market Cap | $618.09B | $1.73B |
Volume | 6,050,983 | 6,198,582 |
Sector | Health | Health |
52-Week High | $278.43 | $14.68 |
52-Week Low | $186.00 | $8.52 |
Typical Hold Time | 129 Days | 72 Days |
Enterprise Value | $646.37B | $3.80B |
Dividend Yield | 2.09% | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
DENTSPLY SIRONA (XRAY) trades at $8.69, down 1.76% on the day and near a 52-week low, reflecting ongoing operational challenges. The stock shows a bearish technical trend with weak moving averages, while fundamentals reveal declining revenue, negative net income margins, and elevated debt levels. Recent Q2 2026 earnings beat expectations but sales fell 4.1%, indicating persistent headwinds in dental markets.
The outlook remains cautious due to margin pressure and competitive threats, though analyst consensus suggests upside to a $13.40 price target. Key risks include execution of the turnaround plan, macroeconomic sensitivity, and high leverage. Investment appeal hinges on successful restructuring and recovery in core dental segments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
